Cargando…

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

BACKGROUND: Histone deacetylases (HDACs) are crucial components of the oestrogen receptor (ER) transcriptional complex. Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-positive breast cancer. This concept was examined in a phase II combination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munster, P N, Thurn, K T, Thomas, S, Raha, P, Lacevic, M, Miller, A, Melisko, M, Ismail-Khan, R, Rugo, H, Moasser, M, Minton, S E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111195/ https://www.ncbi.nlm.nih.gov/pubmed/21559012 http://dx.doi.org/10.1038/bjc.2011.156

Ejemplares similares

Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
por: Raha, Paromita, et al.
Publicado: (2015)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt
por: Thomas, Scott, et al.
Publicado: (2013)

Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
por: Bakhdar, Fatmah A., et al.
Publicado: (2022)

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
por: Hrzenjak, Andelko, et al.
Publicado: (2010)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
por: Eto, Shotaro, et al.
Publicado: (2019)

Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration
por: Wolf, Ines M. L., et al.
Publicado: (2014)

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
por: Phillip, Cornel J, et al.
Publicado: (2012)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
por: Hutt, Darren M., et al.
Publicado: (2014)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat
por: Maxwell, Jill W., et al.
Publicado: (2020)

The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
por: Sarfstein, Rive, et al.
Publicado: (2011)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest
por: Yang, Yang, et al.
Publicado: (2021)

Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension
por: Applegate, Tanya J., et al.
Publicado: (2021)

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
por: LaBonte, Melissa J, et al.
Publicado: (2009)

Crafting Carbazole-Based Vorinostat and Tubastatin-A-like Histone Deacetylase (HDAC) Inhibitors with Potent in Vitro and in Vivo Neuroactive Functions
por: Reddy, R. Gajendra, et al.
Publicado: (2019)

Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia
por: Mettananda, Sachith, et al.
Publicado: (2019)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
por: Pili, Roberto, et al.
Publicado: (2017)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
por: Lorizio, Wendy, et al.
Publicado: (2011)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
por: Ma, Weina, et al.
Publicado: (2020)

Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury
por: Carlisle, Rachel E., et al.
Publicado: (2021)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
por: Vidula, Neelima, et al.
Publicado: (2021)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

The Role of Histone Deacetylase 3 Complex in Nuclear Hormone Receptor Action
por: Ishii, Sumiyasu
Publicado: (2021)

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2020)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vqp4n24uitmnatj99e7bfv4069